Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 open-label extension study of viltolarsen in ambulant boys with Duchenne muscular dystrophy
2023-507146-91-00Phase 3Completed
- Sponsor
- NS Pharma, Inc.
- Start
- Feb 2024
- Modality
- Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 16
01
Overview
Phase 3, open-label, single-arm trial of viltolarsen in Duchenne muscular dystrophy (DMD), sponsored by NS Pharma, Inc. Primary endpoint: Safety assessments. Started Feb 2024; status: completed.
02
Drugs
viltolarsen
03
Conditions
Duchenne muscular dystrophy (DMD)
Beyond the preview
Go deeper on 2023-507146-91-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-507146-91-00.